

Nutrition in Hematology Gene and Cellular Therapy: What to Do?

Andrea Z Pereira^{1,2*}, Lucila Kerbauy¹ and Nelson Hamerschlak¹

¹Oncology and Hematology Department, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil ²Institute of Orthopedics and Traumatology, Hospital das Clínicas, School of Medicine, University of São Paulo, São Paulo, SP, Brazil

*Corresponding Author: Andrea Z Pereira, Oncology and Hematology Department, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

Received: June 24, 2023; Published: July 04, 2023

Abstract

There is a lack of information about nutrition in hematology gene and cellular therapy. The role of nutrition is essential because malnutrition, obesity, and nutrient deficiency are strongly associated with damage to the immune system. A search was conducted on 10 July 2022 using PubMed, comprised of over 33 million citations for biomedical literature from MEDLINE, life science journals, and online books. Databases were screened for search terms in titles and abstracts referring to nutrition, nutrition intervention, gene therapy, Chimeric Antigen Receptor (CAR)-T cell Therapy, and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). This report summarizes interventional nutrition studies in oncology and hematology settings and describes possible nutritional interventions to improve gene and cellular therapy outcomes. The impact of nutrition evaluation and intervention needs to be studied prospectively.

Keywords: Nutrition; Genic Therapy; Car-T Cell; Zinc; Vitamin D; Microbiota; Omega 3

Introduction

Nutritional balance is essential for achieving systemic homeostasis and maintaining normal physiology, a significant challenge for living organisms. Therefore, processes are developed to control systemic nutrient utilization and storage in adipose tissue, liver, and muscle. Anabolic and catabolic processes are essential for an organism to live [1,2].

The nutrition imbalance that damages the immune system is one of the most energy-consuming in the body [2]. The secretion of hormones and cytokines from adipose tissue (adipocytokines) has crucial immune signaling functions and responses. Accordingly, obesity and malnutrition have negatively affected the immune system, increasing infection risk due to having more or less fatty tissue [2].

Obesity has been associated with greater susceptibility to infections (H1N1, influenza, pneumonia, sepsis, etc.); more days in the Intensive Care Unit; more complications in SARSCOV-19; lower antibody formation in flu, hepatitis B, and tetanus vaccines [1-3]. In addition, malnutrition has increased the risk of infections and complications, reduced glucose metabolism, and GLUT1 expression in the T cell [1,2].

Although nutrition has been strongly associated with immune response, there is a lack of studies and guidelines about nutritional intervention in hematology gene and cellular therapy. We believe that is a fundamental issue. Our objective was to discuss possibilities in nutrition therapy for these patients.

Methods

Literature search and study selection

On 08 March 2023, a search was conducted using PubMed, comprised of over 33 million citations for biomedical literature from MED-LINE, life science journals, and online books. Databases screened for search terms in titles and abstracts referring to "nutrition", "nutrition intervention", "gene therapy", "Chimeric Antigen Receptor (CAR) -T cell Therapy", and "Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)".

We used the pre-specified inclusion criteria were adult patients, studies about nutrition, nutrition intervention, gene therapy, CRISPR, Cart-T cell, zinc, vitamin D, microbiota, immune nutrients, and calcium, and full-text articles in English. And the exclusion criteria were patients ≤18 years old and non-full-text articles in a language other than English.

Of the 2198 nutrition studies identified in the literature search, we excluded 2175 because they did not relate to the immune system and gene and cellular therapy. Therefore, we used only 23 studies about nutrition, and immune system, and hematology and only 1 study about nutrition and Car T-cell for this review.

Data extraction for review

Data were extracted for the following outcomes: "gene therapy and nutrition and hematology," "Car-T cell and nutrition," "CRISPR and nutrition and hematology," "gene therapy and immune nutrient and hematology," and "cellular therapy and nutrition".

We found no reports regarding "nutrition intervention protocols", "gene" and "cellular therapy guidelines". This report discusses possible interventional nutrition studies for these brand-new hematology treatments.

Discussion

Gene and cellular therapy

Obesity

Adipose tissue has secreted cytokines and hormones, such as tumor necrosis factor-alpha (TNF- α), which is a well-known pro-inflammatory cytokine essential for the acute phase reaction [1]. Your expression has increased during obesity and decreased following weight loss. Besides, it has been associated with insulin resistance in high-fat diet-induced obesity [1]. In addition to interleukin-6 (IL-6), adipocytes, macrophages, pre-adipocytes, and T cells have been secreted by adipose tissue [1].

In obesity, adipokines such as leptin, resistin, and visfatin, and pro-inflammatory cells, such as macrophages, pro-inflammatory neutrophils, and mast cells, have increased and promoted inflammation. In contrast, the adipokine adiponectin has been decreased and suppressed inflammatory response. The resistin has stimulated the production of TNF- α and IL-12 in macrophages, and visfatin has enabled the production of TNF- α , IL-1 β , and IL-6 [1,2].

In the elderly, a high-fat and caloric diet associated with obesity cause a decline in thymic function, reducing the output of TCR diversity and naive T cells [4].

However, eosinophils, natural killer T cells (NKT cells), and ILC2 cells have been essential in the modulation of immune responses that have been reduced in obese patients. On the other hand, malnutrition has modified adipokines' secretion, decreasing immune cell activation [1].

Although more studies are necessaries, probably, patients with obesity have chemotherapy-resistant or refractory diseases, and CAR T-cell therapy may provide substantial benefits for obesity [5].

Malnutrition

A lack of intake or uptake of nutrition, leading to decreased fat-free mass and body cell mass impairs the disease's clinical outcomes and has been known as malnutrition [4]. This state requires attention once it increases the mortality risk [6,7].

Immune cells, sensitive to nutrient deprivation, have insignificant energy stores, such as glycogen. Primarily, they depend on the uptake of nutrients from their environment to fulfill their energetic necessities. Malnutrition patients have a substantial and fast decrease in splenocytes, thymocytes, and lymphocytes, mainly T cells. Besides, the reduction of immune cell function and increased risk of infectious disease have been reducing fat stores [2].

In malnutrition, leptin is a critical link between nutrition and immune cell biology. Expression of the leptin receptor has been upregulated following T-cell activation. Here we will review findings that demonstrate leptin signaling is required to license pro-inflammatory/ effector T cells for activation metabolically. Changes in adipokine levels mediate communication between nutritional status and T-cell immunity. In addition, low levels of leptin have been associated with elevated death rates from infectious diseases [2].

We observed in CART cell therapy, that there is a tendency to lose 11 - 20% of weight and patients ≥ 50 years with malnutrition to increase the length of stay, there are few conclusive studies about this issue [6]. This therapy has intense inflammation [6]. However, we did not find any study about obesity.

Table 1 summarizes the immune system alteration in patients with obesity and malnutrition.

OBESITY MALNUTRITION IMMUNE FUNCTION LEPTIN HIGH LOW Pleiotropic hormone with many targets and many functions in immune cells Induces Th1 and Th17 polarization Polarization of monocytes and macrophages toward M2 phenotype Suppresses NK cell, eosinophil, neutrophil, yδ T cell, and dendritic cell activation and inflammatory cytokine production T cell Glut1 LOW UNKNOWN Polarization of monocytes and macrophages toward M2 phenotype Suppresses NK cell, eosinophil, neutrophil, yδ T cell, and dendritic cell activation and inflammatory cytokine production T cell Glut1 LOW Modulating and improving insulin resistance expression macrophage polarization metrophil, yδ T cell, and dendritic cell activation and inflammatory cytokine production Treg cell LOW HIGH LOW Altering macrophage polarization Number and LOW HIGH Producing IL-6 and IFN-g, which leads to functional plasticity of Treg cells Intract not Neutrophil chemotaxis Inhibits IL-1α and IL-1β activity M1 macrophages HIGH UNKNOWN Stimulates macrophage activity IL-18 MIP-10,MIP-1β Neutrophil chemotaxis Induces MIL-19 LOW						
Adiponectin LOW UNKNOWN Polarization Adiponectin LOW UNKNOWN Polarization of monocytes and macrophages toward M2 phenotype Suppresses NK cell, eosinophil, neutrophil, γδ T cell, and dendritic cell activation and inflammatory cytokine production T cell Glut1 LOW Modulating and improving insulin resistance expression Modulating and improving insulin resistance The proportion of Treg cell HIGH LOW Number and function of Teff LOW HIGH Producing IL-6 and IFN-g, which leads to functional plasticity of Treg cells Rells Neutrophil chemotaxis TNFα MI macrophages HIGH UNKNOWN Stimulates macrophage activity CRP Enhances macrophage migration IL-1RA Stimulates the production of TNF-α, IL-1β, and IL-6 IL-18 HIGH LOW MIP-1α,MIP-1β HIGH Macrophage recruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages Induces MCP1 HIGH LOW Inhibits macrophage migration IL3 LOW HIGH Macrophage recruitment Inhibits MIF HIGH		OBESITY	MALNUTRITION	IMMUNE FUNCTION		
AdiponectinLOWUNKNOWNPolarizationPolarizationAdiponectinLOWUNKNOWNPolarization of monocytes and macrophages toward M2 phenotype Suppresses NK cell, eosinophil, neutrophil, yδ T cell, and dendritic cell activation and inflammatory cytokine productionTcell Glut1LOWModulating and improving insulin resistance expressionThe proportion ofHIGHLOWAltering macrophage polarizationNumberandLOWAltering macrophage polarizationNumberandLOWHIGHProducing IL-6 and IFN-g, which leads to functional plasticity of Treg cellsNumberandLOWHIGHProducing IL-6 and IFN-g, which leads to functional plasticity of Treg cellsNumberandLOWNeutrophil chemotaxis Inhibits IL-1α and IL-1β activityM1 macrophagesHIGHUNKNOWNStimulates macrophage activityCRPEnhances macrophage migrationIL-1RA IL-1βII-1βMIP-1α,MIP-1βIIGHLOWIL 6HIGHLOWIRGHLOWInducesMCP1HIGHLOWInducesInducesMIFHIGHLOWII.3LOWHIGHMIFHIGHLOWII.3LOWII.3HIGHLOWInduces neutrophage ingrationII.3HIGHLOWIIInterleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage ingrationII.3HIGHLOWIIInterleukin; TNFα -tumor necro	LEPTIN	HIGH	LOW			
AdiponectinLOWPolarizationAdiponectinLOWUNKNOWNPolarization of monocytes and macrophages toward M2 phenotype Suppresses NK cell, eosinophil, neutrophil, γδ T cell, and dendritic cell activation and inflarmatory cytokine productionTcellGlut1LOWModulating and improving insulin resistance expressionThe proportion ofHIGHLOWAltering macrophage polarizationNumberandLOWHIGHProducing IL-6 and IFN-g, which leads to functional plasticity of Treg cellsNumberandLOWHIGHProducing IL-6 and IFN-g, which leads to functional plasticity of Treg cellsB cellsNeutrophil chemotaxis Inhibits IL-1α and IL-1β activityStimulates macrophage activityCRPHIGHUNKNOWNStimulates macrophage activityIL-1RA IL-1A, MIP-1βLOWRecruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages InducesMCP1HIGHLOWInhibits macrophage migrationIL33LOWHIGHMacrophage recruitment InhibitsMIFHIGHLOWInhibits macrophage migrationIL3LOWHIGHMaintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage polarizationIL3HIGHLOWInduces neutrophil chemotaxisIL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage injammatory protein. CRP-c reactive protein; MIF-macrophage migrationIL4HIGHLOWInduces neutrophil chemotaxisIL-in						
AdiponectinLOWUNKNOWNPolarization of monocytes and macrophages toward M2 phenotype Suppresses NK cell, eosinophil, neutrophil, yδ T cell, and dendritic cell activation and inflammatory cytokine productionTcellGlut1LOWModulating and improving insulin resistance expressionThe proportion of reg cellHIGHLOWAltering macrophage polarizationNumberand plasticity of Treg cellsProducing IL-6 and IFN-g, which leads to functional plasticity of Treg cellsB cellsLOWHIGHUNKNOWNTNFαNeutrophil chemotaxis Inhibits IL-1α and IL-1β activityM macrophagesHIGHUNKNOWNIL-1RAStimulates macrophage activityIL-1βHIGHLOWMIF-1α,MIP-1βHIGHLOWIL 6HIGHLOWMIFHIGHLOWIL33LOWHIGHIL3LOWInhibits macrophage recruitment InhibitsIL3LOWHIGHMIFHIGHLOWIL3LOWInhibits macrophage recruitment InhibitsIL8HIGHLOWIL9Inhibits macrophage polarizationIL9LOWInducesIL-interleukin; TNFa - tumor necrosis factor-alpha; MIP-macrophage polarizationIL9LOWInduces neutrophil chemotaxisIL-interleukin; TNFa - tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-c reactive protein; MIF-macrophage migrationIL8HIGHLOWIL-interleukin; TNFa - tumor necrosis factor-alpha; MIP-macrophage				Induces Th1 and Th17 polarization		
M2phenotypeSuppressesNK cell, eosinophil, neutrophil, γδ T cell, and dendritic cell activation and inflammatory cytokine productionTcellGlut1LOWModulating and improving insulin resistance expressionThe proportion of Treg cellHIGHLOWAltering macrophage polarizationNumberand function of TeffLOWHIGHProducing IL-6 and IFN-g, which leads to functional plasticity of Treg cellsS cellsNeutrophil chemotaxis Inhibits IL-1α and IL-1β activityNeutrophil chemotaxis Inhibits IL-1α and IL-1β activityM1 macrophagesHIGHUNKNOWNStimulates macrophage activity Enhances macrophage activityCRPHIGHLOWRecruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages InducesMCP1HIGHLOWInhibits macrophage migrationIL33LOWHIGHMacrophage recruitment InhibitsIL8HIGHLOWInhibits macrophage polarizationIL8HIGHLOWInhibits macrophage polarizationIL9LOWHIGHMacrophage resultment InhibitsIL-Interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage polarizationInducesIL8HIGHLOWInduces neutrophil chemotaxisIL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage migrationInflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factorHIGH:HIGHLOWInduces neutrophil chemotaxisIL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophag				Polarization		
reductionneutrophil, γδ T cell, and dendritic cell activation and inflammatory cytokine productionT cell Glut1LOWModulating and improving insulin resistance expressionThe proportion of Treg cellHIGHLOWAltering macrophage polarizationNumber and function of Teff cellLOWHIGHProducing IL-6 and IFN-g, which leads to functional plasticity of Treg cellsB cells TNFα M1 macrophagesHIGHUNKNOWNNeutrophil chemotaxis Inhibits IL-1α and IL-1β activityCRP IL-1RA IL-1β IL-1βUNKNOWNStimulates macrophage activity Enhances macrophage migrationIL 6HIGHLOWRecruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages InducesMCP1HIGHLOWInhibits macrophage migrationIL33LOWHIGHMacrophage recruitment InhibitsIL33LOWHIGHMintains adjose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factorIL8HIGHLOWInducesHIGH:LOWInduces neutrophil chemotaxisIL-interleukin; TNFα - tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factorHIGH:HIGHLOWInduces neutrophil chemotaxisIL-interleukin; TNFα - tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factorHIGH:HIG	Adiponectin	LOW	UNKNOWN	Polarization of monocytes and macrophages toward		
T cellGlut1LOWModulating and improving insulin resistanceexpressionHIGHLOWAltering macrophage polarizationTreg cellAltering macrophage polarizationNumberandLOWHIGHfunction of TeffProducing IL-6 and IFN-g, which leads to functional plasticity of Treg cellsB cellsNumberNeutrophil chemotaxisTNFαHIGHUNKNOWNStimulates macrophage activityCRPEnhances macrophage migrationIL-1βStimulates the production of TNF-α, IL-1β, and IL-6IL-1βHIGHLOWRecruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages InducesMCP1HIGHLOWInhibits macrophage migrationIL3LOWHIGHLOWIL8HIGHLOWIL9Inhibits macrophage migrationIL4LOWInhibits macrophage migrationIL3LOWHIGHMIFHIGHLOWHIGHLOWInhibits macrophage migrationIL3LOWHIGHIL4LOWInhibits macrophage migrationIL5HIGHLOWIL6HIGHHIGHLOWHIGHLOWIL9Maintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factorHIGH:HIGHLOWHIGH:LOWHIGH:LOW <td></td> <td></td> <td></td> <td>M2 phenotype Suppresses NK cell, eosinophil,</td>				M2 phenotype Suppresses NK cell, eosinophil,		
TcellGlut1LOWModulating and improving insulin resistanceThe proportion of Treg cellHIGHLOWAltering macrophage polarizationNumberand function of TeffLOWHIGHProducing IL-6 and IFN-g, which leads to functional plasticity of Treg cellsB cellsNumberHIGHUNKNOWNNeutrophil chemotaxis Inhibits IL-1α and IL-1β activity Stimulates macrophage migrationTL-1RAUNKNOWNStimulates macrophage activity Enhances macrophage migrationIL-1RALOWHIGHLOWRCP1HIGHLOWRecruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages InducesMIFHIGHLOWInhibits macrophage migrationIL33LOWHIGHMaintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage polarizationIL8HIGHLOWInhibits macrophage nigrationIL-1R+LOWInducesMIF+HIGHLOWHIGH+LOWInhibits macrophage nigrationIL8HIGHLOWInhibits macrophage nigrationIL9LOWHIGHInducesIL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factorHIGH:High-quality prospective cohort, retrospective cohort study with adequate power or systematic review of these studies; LOW:				neutrophil, $\gamma\delta$ T cell, and dendritic cell activation		
expressionAttering macrophage polarizationThe proportion of Treg cellHIGHLOWAltering macrophage polarizationNumber function of Teff cellLOWHIGHProducing IL-6 and IFN-g, which leads to functional plasticity of Treg cells8 cells TNFα M1 macrophagesNeutrophil chemotaxis Inhibits IL-1α and IL-1β activityTNFa M1 macrophagesHIGHUNKNOWNStimulates macrophage activity Enhances macrophage migrationIL-1RA IL-1β IL-1βStimulates the production of TNF-α, IL-1β, and IL-6IL<1β MIP-1α,MIP-1βLOWRecruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages InducesMCP1HIGHLOWInhibits macrophage migrationIL3LOWHIGHMaintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factorIL8HIGHLOWInducesIL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factorHIGH: High-quality prospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from				and inflammatory cytokine production		
The proportion of Treg cellHIGHLOWAltering macrophage polarizationNumber function of Teff cellLOWHIGHProducing IL-6 and IFN-g, which leads to functional plasticity of Treg cellsB cells TNFαNeutrophil chemotaxis Inhibits IL-1α and IL-1β activityNeutrophil chemotaxis Inhibits IL-1α and IL-1β activityM1 macrophages IL-1RA IL-1βHIGHUNKNOWNStimulates macrophage migration Stimulates the production of TNF-α, IL-1β, and IL-6IL IL IL ILHIGHLOWRecruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages InducesMCP1HIGHLOWInhibits macrophage migrationIL3LOWHIGHMaintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factorIL8HIGHLOWInducesIL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factorHIGH: HIGH: High-quality prospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study with adequate power or systematic review of these	T cell Glut1	LOW		Modulating and improving insulin resistance		
Treg cell LOW HIGH Producing IL-6 and IFN-g, which leads to functional plasticity of Treg cells Number and function of Teff cell Neutrophil chemotaxis Inhibits IL-1α and IL-1β activity B cells NFa Neutrophil chemotaxis Inhibits IL-1α and IL-1β activity TNFα NI macrophages HIGH UNKNOWN Stimulates macrophage activity CRP Enhances macrophage migration Stimulates the production of TNF-α, IL-1β, and IL-6 IL-1RA IL6 HIGH LOW Recruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages Induces MCP1 HIGH LOW Inhibits macrophage migration IL33 LOW HIGH Maintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage nolarization IL8 HIGH LOW Induces neutrophil hemotaxis IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-uality prospective cohort, retrospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	expression					
Number function of Teff cellLOWHIGHProducing IL-6 and IFN-g, which leads to functional plasticity of Treg cellsB cells TNFα M1 macrophagesNeutrophil chemotaxis Inhibits IL-1α and IL-1β activityNeutrophil chemotaxis Inhibits IL-1α and IL-1β activityIL-1RA IL-1βUNKNOWNStimulates macrophage activity Enhances macrophage migrationIL-1RA IL-1βHIGHLOWRecruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages InducesMCP1HIGHHIGHMacrophage recruitment InhibitsMIFHIGHLOWInhibits macrophage migrationIL3LOWHIGHMacrophage recruitment InhibitsILHIGHLOWInhibits macrophage migrationIL3LOWHIGHMaintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage nolarizationIL3HIGHLOWInduces neutrophil chemotaxisIL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factorHIGH: HIGH: High-quality prospective cohort, retrospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	The proportion of	HIGH	LOW	Altering macrophage polarization		
function of Teff cell plasticity of Treg cells B cells Neutrophil chemotaxis TNFα Neutrophil chemotaxis M1 macrophages HIGH UNKNOWN Stimulates macrophage activity Enhances macrophage activity CRP Enhances macrophage migration IL-1RA Stimulates the production of TNF-α, IL-1β, and IL-6 IL-1β NIP-1α,MIP-1β IL 6 HIGH LOW RCP1 HIGH LOW MIF HIGH LOW IL33 LOW HIGH IL8 HIGH LOW IL8 HIGH LOW IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor	Treg cell					
cell Photo Page Mark y Program B cells Neutrophil chemotaxis TNFα Inhibits IL-1α and IL-1β activity MI macrophages HIGH UNKNOWN CRP Enhances macrophage activity IL-1RA Stimulates the production of TNF-α, IL-1β, and IL-6 IL-1β Stimulates the production of TNF-α, IL-1β, and IL-6 MIP-1α,MIP-1β ILG IL 6 HIGH LIGH LOW RCP1 HIGH HIGH LOW IL33 LOW HIGH LOW IL8 HIGH LOW Inhibits macrophage inflammatory protes alternatively activated macrophage polarization IL8 HIGH LOW IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort, retrospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	Number and	LOW	HIGH	Producing IL-6 and IFN-g, which leads to functional		
B cells Neutrophil chemotaxis TNFα Inhibits IL-1α and IL-1β activity M1 macrophages HIGH UNKNOWN Stimulates macrophage migration Stimulates macrophage migration IL-1RA Stimulates the production of TNF-α, IL-1β, and IL-6 IL-1β MIP-1α,MIP-1β IL 6 HIGH LOW Recruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages induces MCP1 HIGH LOW MIF HIGH LOW IL33 LOW HIGH IL8 HIGH LOW ILeinterleukin; TNFα - tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH LOW Induces neutrophil chemotaxis IL-interleukin; TNFα - tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort, retrospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	function of Teff			plasticity of Treg cells		
TNFα HIGH UNKNOWN Inhibits IL-1α and IL-1β activity M1 macrophages HIGH UNKNOWN Stimulates macrophage activity CRP Enhances macrophage migration Stimulates the production of TNF-α, IL-1β, and IL-6 IL-1β MIP-1α,MIP-1β Stimulates the production of TNF-α, IL-1β, and IL-6 IL 6 HIGH LOW Recruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages induces MCP1 HIGH LOW Inhibits macrophage migration IL3 LOW HIGH Maintains adjose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH LOW Induces HIGH LOW Induces neutrophil chemotaxis IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	cell					
M1 macrophages CRP HIGH UNKNOWN Stimulates macrophage activity IL-1RA Enhances macrophage migration Stimulates the production of TNF-α, IL-1β, and IL-6 IL-1β MIP-1α,MIP-1β Stimulates the production of TNF-α, IL-1β, and IL-6 IL 6 HIGH LOW Recruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages induces MCP1 HIGH HIGH Macrophage recruitment Inhibits MIF HIGH LOW Inhibits macrophage migration IL33 LOW HIGH Maintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage polarization IL8 HIGH LOW Induces neutrophil chemotaxis IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	B cells			Neutrophil chemotaxis		
CRP Enhances macrophage migration IL-1RA Stimulates the production of TNF-α, IL-1β, and IL-6 IL-1β MIP-1α,MIP-1β IL 6 HIGH LOW Recruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages Induces MCP1 HIGH HIGH MIF HIGH LOW IL33 LOW HIGH MIB LOW Inhibits macrophage migration IL3 LOW HIGH MIE HIGH LOW IL4 LOW Inhibits macrophage migration IL3 LOW HIGH MIF HIGH LOW IL4 HIGH Maintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage polarization IL8 HIGH LOW IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort, study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	ΤΝFα			Inhibits IL-1a and IL-1β activity		
IL-1RA IL-1RA Stimulates the production of TNF-α, IL-1β, and IL-6 IL-1β MIP-1α,MIP-1β Recruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages induces IL 6 HIGH LOW Recruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages induces MCP1 HIGH HIGH Macrophage recruitment Inhibits MIF HIGH LOW Inhibits macrophage migration IL33 LOW HIGH Maintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage polarization IL8 HIGH LOW Induces neutrophil chemotaxis IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort, retrospective cohort study, untreated controls from	M1 macrophages	HIGH	UNKNOWN	Stimulates macrophage activity		
IL-1β MIP-1α,MIP-1β IL 6 HIGH LOW Recruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages Induces MCP1 HIGH HIGH Macrophage recruitment Inhibits MIF HIGH LOW Inhibits macrophage migration IL33 LOW HIGH Maintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage polarization IL8 HIGH LOW Induces IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort, retrospective cohort study, untreated controls from	CRP			Enhances macrophage migration		
MIP-1α,MIP-1β MIP-1α,MIP-1β IL 6 HIGH LOW Recruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages induces MCP1 HIGH HIGH Macrophage recruitment Inhibits MIF HIGH LOW Inhibits macrophage migration IL33 LOW HIGH Maintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage polarization IL8 HIGH LOW Induces IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	IL-1RA			Stimulates the production of TNF- α , IL-1 β , and IL-6		
IL 6 HIGH LOW Recruitment of macrophages; polarization toward pro-inflammatory classically activated macrophages Induces MCP1 HIGH HIGH Macrophage recruitment Inhibits MIF HIGH LOW Inhibits macrophage migration IL33 LOW HIGH Maintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage polarization IL8 HIGH LOW Induces neutrophil chemotaxis IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage migration inhibitory factor Rep-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort, study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	IL-1β					
MCP1 HIGH HIGH Macrophage recruitment Inhibits MIF HIGH LOW Inhibits macrophage migration IL33 LOW HIGH Maintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage polarization IL8 HIGH LOW Induces neutrophil chemotaxis IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage migration inhibitory factor Induces neutrophil chemotaxis HIGH: High-quality prospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	ΜΙΡ-1α,ΜΙΡ-1β					
MCP1 HIGH Macrophage recruitment Inhibits MIF HIGH LOW Inhibits macrophage migration IL33 LOW HIGH Maintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage polarization IL8 HIGH LOW Induces neutrophil chemotaxis IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	IL 6	HIGH	LOW	Recruitment of macrophages; polarization toward		
MCP1 HIGH HIGH Macrophage recruitment Inhibits MIF HIGH LOW Inhibits macrophage migration IL33 LOW HIGH Maintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage polarization IL8 HIGH LOW Induces neutrophil chemotaxis IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort, study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from				pro-inflammatory classically activated macrophages		
MIF HIGH LOW Inhibits macrophage migration IL33 LOW HIGH Maintains adipose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage polarization IL8 HIGH LOW Induces neutrophil chemotaxis IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort, retrospective cohort study, untreated controls from				Induces		
IL33 LOW HIGH Maintains adjpose tissue-resident Treg cell function, promotes Th2 response, promotes alternatively activated macrophage polarization IL8 HIGH LOW Induces neutrophil chemotaxis IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	MCP1	HIGH	HIGH	Macrophage recruitment Inhibits		
μ promotes Th2 response, promotes alternatively activated macrophage polarization IL8 HIGH LOW Induces neutrophil chemotaxis IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	MIF	HIGH	LOW	Inhibits macrophage migration		
IL8 HIGH LOW Induces neutrophil chemotaxis IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	IL33	LOW	HIGH	Maintains adipose tissue-resident Treg cell function,		
IL8 HIGH LOW Induces neutrophil chemotaxis IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from				promotes Th2 response, promotes alternatively		
IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein. CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from				activated macrophage polarization		
CRP-C reactive protein; MIF-macrophage migration inhibitory factor HIGH: High-quality prospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	IL8	HIGH	LOW	Induces neutrophil chemotaxis		
HIGH: High-quality prospective cohort study with adequate power or systematic review of these studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	IL-interleukin; TNFα -tumor necrosis factor-alpha; MIP-macrophage inflammatory protein.					
studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from	CRP-C reactive protein; MIF-macrophage migration inhibitory factor					
	HIGH: High-quality prospective cohort study with adequate power or systematic review of these					
an RCT, or systematic review of these studies; UNKNOWN: Not know evidence and studies results	studies; LOW: Lesser quality prospective cohort, retrospective cohort study, untreated controls from					
	an RCT, or systematic review of these studies; UNKNOWN: Not know evidence and studies results					

	Table 1: Syst	tem immune in	patients with obesity	y and malnutrition(1,2)
--	---------------	---------------	-----------------------	-------------------------

Nutrients of immunity

Healthy food has been associated with better system immune cells, mainly glutamine, glucose, amino acids, principally leucine, tryptophan, arginine and serine, and fatty acids [7].

Arginine is essential to decrease T cell dysfunction and injury; increase lymphocytic IL-2; increase tumor lysis by macrophages; increase nitric oxide formation; increase lymphocyte mitotic response; stimulate the production of G.H.; T-helper cell increase [8,9].

Fatty acids omega 3 is related to reduced cytokine response to inflammation; the decreased ability of leukocytes to produce inflammatory cytokines; the action of prostaglandins and leukotrienes; natural killer, and T cell mediation. Besides, nucleotides improve T-cell function [8,9].

Metabolically T cells have been affected by [10]:

- 1. Substrate transport: Reduction of amino acid transport has limited effector T cell expansion and blocking glucose uptake or inhibiting lactate export has inhibited effector T cell development. T reg could be blocked by inhibiting fatty acid uptake glycolysis.
- Glycolysis: Lactate production and Inhibiting glycolysis have inhibited effector T cells, and restricting glycolysis can promote cell longevity, limit terminal differentiation, and have a memory phenotype.
- 3. Fatty acid synthesis: Reduction of fatty acid synthesis could promote T reg development and impair Th17 differentiation.
- 4. Fatty acid oxidation: Enhancing fatty acid oxidation has promoted memory cell development or Treg.
- 5. Glutaminolysis: Glutaminolysis and reductive carboxylation inhibiting glutamine metabolism have inhibited effector T cell development and T cell proliferation.
- Fatty: Mitochondrial function and enhancing mitochondrial function through increasing mass, altering mitochondrial dynamics may support T cell longevity or mitochondrial oxidative phosphorylation system (OXPHOS).

In addition, some studies showed, in animal models, dietary restriction of caloric intakes, such as starvation or a fasting-mimicking diet or intermittent fasting, has been associated with enhancing anti-tumor immune function, acting mainly in CD8⁺ T-cell and macro-phages [4]. More studies in human models will be necessary to certify these findings and to define how much caloric reduction.

Microbiome

It has been responsible for producing essential vitamins and trace elements, resistance to enteropathogens, inhibiting pathogenic growth, immune response, and production of short-chain fatty acids. Besides, the microbiome has been changed by drug use (antibiotics and anti-inflammatory drugs), diet, and aging [11].

The microbiome has been classified as positive - high diversity and abundance of *Ruminococcaceae* and *Faecalibacterium* - or negative - reduced diversity and increased relative abundance of *Bacteroidales*. In oncology, a positive microbiome stimulates a systemic and anti-tumor immune response. It has therapeutic potential in immunotherapy and CART cells [12,13].

According to Spencer., *et al.* [14], a balanced diet rich in fibers had better immunotherapy results than probiotic use because a healthy diet promotes a favorable microbiome with high diversity.

Vitamin D

Vitamin D has been associated with antimicrobial, anti-inflammatory, and antioxidant effects; maintenance of functional and structural integrity of mucosal cells in innate barriers; normal functioning of T cells; antibody production and antigen responses; reduction of the respiratory tract and lung infection risk; alleviation of the inflammatory response is an adequate immunoregulatory function [15,16].

The serum levels of vitamin D and BMI \ge 30 kg/m² have been inversely proportional, explained by the body fat kidnap the fat-soluble vitamin [15]. Moreover, vitamin D deficiency is common among the elderly. We found low levels of vitamin D in 5% to 25% of the independent elderly and 60 to 80% of institutionalized patients [14]. This is important because low levels of vitamin D have contributed to the reduction of immune tolerance and organ-specific or systemic autoimmune diseases associated with mechanisms that finally progress to T cells or reactive B [16].

Low vitamin D levels were associated with lower cell viability of the infused CAR-T product, the worst 100-day complete response, and low overall survival [17]. Besides, gut microbial metabolites and ligands have modified CAR-T cells and T cells. T cell differentiation and change effector functions depend on bile acid metabolites acting on vitamin D receptors in the intestinal mucosa [15]. Important emphasis on supplement nutrients for treating deficiencies is essential; however, in patients with normal levels could cause side effects, such as fractures in unnecessary vitamin D supplementation [18].

Calcium

The symptoms of cytokine release syndrome (CRS), which is one important complication of CAR-T cell therapy, are very similar to calcium deficiency [19,20]. CRS has neurological symptoms: headaches, confusion, hallucinations, delirium, aphasia, paresis, and seizures [19]. Similarly, hypocalcemia has seizures, confusion, disorientation, and paresthesia [21]. For this reason, in clinical practice, there is a suggestion for evaluating hypocalcemia in these patients as a differential diagnosis of CRS.

Zinc

Zinc, indispensable for diverse cell functions, is an important trace element and a cofactor of an estimated 3000 human proteins. Zinc deficiency acts on the immune system, such as T-cell development and activation. Therefore, zinc level restoration improves immune function and decreases the incidence of infections in patients with zinc deficiency [22,23]. This nutrient might be evaluated in gene and cellular treatment patients.

Nutrition approach in hematology gene and cellular therapy

Gene and cellular therapy are brand-new; therefore, there are few studies about the nutrition approach. Based on our discussion, we believe that obesity and malnutrition could be prognostic factors in these therapies. Immunonutrition, vitamin D, zinc, and calcium are essential for the immune system and should be evaluated before and during these treatments.

A positive microbiome is associated with a healthy and balanced diet; therefore, our patients should have this nutrition recommendation. Use or not-use probiotics must be more studied as an attractive strategy in this group.

Conclusion

In conclusion, editing and cellular therapy are costly, so every strategy is important. Nutrition is considered a non-expensive and practical intervention, hence must be more studied to improve prognosis and reduce complications.

Conflicts of Interest

None.

Financial Support

None.

05

Bibliography

- Alwarawrah Y., *et al.* "Changes in nutritional status impact immune cell metabolism and function". *Frontiers in Immunology* 9 (2018): 1-14.
- 2. Cohen S., et al. "Nutritional effects on T-cell immunometabolism". European Journal of Immunology 47.2 (2017): 225-235.
- 3. Yuwono A., et al. "Effect of increased BMI and obesity on the outcome of COVID-19 adult patients: A systematic review and metaanalysis". Diabetes and Metabolic Syndrome: Clinical Research and Reviews 14 (2020): 1897-1904.
- 4. Drijvers JM., et al. "The effects of age and systemic metabolism on anti-tumor t cell responses". Elife 9 (2020): 1-29.
- 5. Faruqi AJ., et al. "The Impact of Race, Ethnicity, and Obesity on CAR T-cell Therapy Outcomes". Blood Advances (2022).
- 6. Cucchiaro B and Weekes CE. "A systematic review of nutrition support interventions in adult haematology and oncology patients receiving CAR T cell therapy". *Clinical Nutrition ESPEN* 46 (2021): 60-55.
- Kedia-Mehta N and Finlay DK. "Competition for nutrients and its role in controlling immune responses". *Nature Communications* 10.1 (2019): 1-8.
- 8. De Luis DA., *et al.* "Effect of c-reactive protein and interleukins blood levels in postsurgery arginine-enhanced enteral nutrition in head and neck cancer patients". *European Journal of Clinical Nutrition* 57.1 (2003): 96-99.
- 9. BRB. "Practical recommendations for immune-enhancing diets". Journal of Nutrition 134.10 (2004): 2868S-2872S.
- 10. O'Sullivan D and Pearce EL. "Targeting T cell metabolism for therapy". Trends in Immunology 36.2 (2015): 71-80.
- 11. Klein GL., *et al.* "Gut barrier dysfunction and microbial translocation in cancer cachexia: A new therapeutic target". *Current Opinion in Supportive and Palliative Care* 7.4 (2013): 361-367.
- Gopalakrishnan V., *et al.* "Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients". *Science* 359.6371 (2018): 97-103.
- 13. Abid MB., et al. "Gut microbiome and CAR-T therapy". Experimental Hematology and Oncology 8.1 (2019): 1-10.
- 14. Christine N Spencer., *et al.* "The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors". *Cancer Research* 79.13 (2019).
- Schubert ML., et al. "The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy". Frontiers in Immunology 12 (2021): 1-19.
- 16. Chen Y., et al. "Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases". Journal of Immunology Research (2019).
- 17. Nath K., et al. "Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma". Transplantation and Cellular Therapy (2022).
- 18. LeBoff MS., *et al.* "Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults". *The New England Journal of Medicine* 37.4 (2022): 299-309.
- 19. Shimabukuro-Vornhagen A., et al. "Cytokine release syndrome". The Journal for ImmunoTherapy of Cancer 6.1 (2018).

- Wang N., *et al.* "Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies". *Blood* 135.1 (2020): 17-27.
- 21. Fong J. "Clinical review: hypocalcemia". Canadian Family Physician 58.2 (2012): 158-162.
- 22. Rosenkranz E., *et al.* "Zinc supplementation induces regulatory T cells by inhibition of Sirt-1 deacetylase in mixed lymphocyte cultures". *Molecular Nutrition and Food Research* 60.3 (2016): 661-671.
- 23. Pereira AZ., *et al.* "Challenging and practical aspects of nutrition in chronic graft-versus-host disease". *Biology of Blood and Marrow Transplantation* (2020).

Volume 18 Issue 7 July 2023 ©All rights reserved by Andrea Z Pereira., *et al.*